Answers are grounded in this paper and cite their sources.
BACKGROUND: In 4 clinical studies of a biological tissue isolate (BTI) similar to Rellidep, the majority of subjects reported improved well-being and mood. Based on these reports of positive effect on mood in trials, an antidepressant pilot study was undertaken with the BTI Rellidep. METHOD: Twenty-three subjects (14 women and 9 men; mean age, 44.8 years) with major depressive disorder entered an 8-week trial of Rellidep with a 17-item Hamilton Depression Rating Scale (HAM-D) score of 18 or above. Three subjects dropped out before beginning treatment, leaving an intention-to-treat (ITT) sample of 20. Sixteen subjects completed the trial. All patients received Rellidep 1000 mg (500 mg × 2) twice a day orally daily for 8 weeks. No other treatments were permitted except for intermittent lorazepam for sleep if necessary. The primary response to treatment outcome was a 50% decline on the HAM-D. Secondary measures included the Beck Depression Inventory, Montgomery-Åsberg Depression Rating Scale, Clinical Global Impression, Hamilton Rating Scale for Anxiety, Medical Outcomes Study Short-Form 36, and Arizona Sexual Experience Scale. RESULTS: The overall response rate was 75% (15/20). Almost 87% of those who responded did so by week 4. The data analysis of change scores indicates that for the ITT population the decrease in the HAM-D was statistically significant (P < 0.001). On all other measures, improvement from baseline was statistically significant (P < 0.001), except for the Arizona Sexual Experience Scale (ITT: P = 0.055). There were no significant adverse events. CONCLUSIONS: The positive outcome of this open trial indicates that Rellidep may be an effective and safe antidepressant. Further placebo-controlled trials are indicated.
No takes yet. Share an insight, caveat, or question.
Sadavoy et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: